Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia

CD73 Participates in Cellular Multiresistance Program and Protects against TRAIL-Induced Apoptosis

(2014) A. Mikhailov et al.   JOURNAL OF IMMUNOLOGY

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

(2009) Monique L Den Boer et al.   LANCET ONCOLOGY

Deletion ofIKZF1and Prognosis in Acute Lymphoblastic Leukemia

(2009) Charles G. Mullighan et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK mutations in high-risk childhood acute lymphoblastic leukemia

(2009) C. G. Mullighan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

(2008) C. Langer et al.   BLOOD

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Prediction of relapse in paediatric pre-B acute lymphoblastic leukaemia using a three-gene risk index

(2008) Katrin Hoffmann et al.   BRITISH JOURNAL OF HAEMATOLOGY

Gene Expression Signatures Predictive of Early Response and Outcome in High-Risk Childhood Acute Lymphoblastic Leukemia: A Children's Oncology Group Study

(2008) Deepa Bhojwani et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute lymphoblastic leukaemia

(2008) Ching-Hon Pui et al.   LANCET

The bone morphogenetic protein pathway is active in human colon adenomas and inactivated in colorectal cancer

(2007) Liudmila L. Kodach et al.   CANCER